MCID: SCH012
MIFTS: 54

Schizoaffective Disorder

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Schizoaffective Disorder

MalaCards integrated aliases for Schizoaffective Disorder:

Name: Schizoaffective Disorder 12 76 25 55 15 73
Schizophreniform Psychosis, Affective Type 25
Schizophrenia, Schizo-Affective Type 25
Schizo-Affective Type Schizophrenia 25
Schizoaffective Schizophrenia 25
Schizo-Affective Psychosis 25
Schizoaffective Psychosis 25

Classifications:



External Ids:

Disease Ontology 12 DOID:5418
ICD10 33 F25 F25.9
ICD9CM 35 295.7
MeSH 44 D011618
NCIt 50 C94378
SNOMED-CT 68 68890003
UMLS 73 C0036337

Summaries for Schizoaffective Disorder

Genetics Home Reference : 25 Schizoaffective disorder is a mental health condition that includes features of both schizophrenia and a mood disorder such as bipolar disorder or depression. The prefix "schizo-" refers to the psychotic symptoms of schizophrenia that affect a person's thinking, sense of self, and perceptions. The term "-affective" refers to extreme shifts in mood, energy, and behavior.

MalaCards based summary : Schizoaffective Disorder, also known as schizophreniform psychosis, affective type, is related to schizophrenia 2 and depression. An important gene associated with Schizoaffective Disorder is DISC2 (Disrupted In Schizophrenia 2), and among its related pathways/superpathways are Neuroscience and Monoamine GPCRs. The drugs Dopamine and Risperidone have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and cortex, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A psychotic disorder that is characterized by recurring episodes of mood fluctuations and a loss of contact with reality.

Wikipedia : 76 Schizoaffective disorder (SZA, SZD or SAD) is a mental disorder characterized by abnormal thought... more...

Related Diseases for Schizoaffective Disorder

Diseases related to Schizoaffective Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 120)
# Related Disease Score Top Affiliating Genes
1 schizophrenia 2 31.5 DISC1 DISC2
2 depression 30.6 BDNF DISC2 HTR2A SLC6A4
3 schizophreniform disorder 30.5 COMT DRD2 PRL
4 endogenous depression 30.3 BDNF HTR2A SLC6A4
5 tardive dyskinesia 30.2 COMT DRD2 DRD3 HTR2A
6 anxiety 30.2 BDNF COMT HTR2A SLC6A4
7 bipolar i disorder 30.2 BDNF COMT DTNBP1 HTR2A SLC6A4
8 hyperprolinemia 30.1 COMT PRODH
9 borderline personality disorder 30.1 BDNF COMT HTR2A SLC6A4
10 delusional disorder 30.1 DRD2 DRD3
11 personality disorder 30.0 BDNF COMT DRD2 HTR2A PRL SLC6A4
12 paranoid schizophrenia 30.0 BDNF COMT HTR2A SLC6A4
13 cocaine dependence 30.0 DRD2 DRD3 SLC6A4
14 early-onset schizophrenia 29.9 BDNF DRD2 HTR2A
15 schizophrenia 29.9 BDNF COMT DAOA DISC1 DISC2 DRD2
16 schizotypal personality disorder 29.9 COMT SULT4A1
17 pathological gambling 29.8 DRD2 DRD3 HTR2A SLC6A4
18 tobacco addiction 29.8 COMT DRD2 HTR2A SLC6A4
19 obsessive-compulsive disorder 29.7 BDNF COMT DRD2 DRD3 HTR2A PRL
20 anorexia nervosa 29.6 BDNF COMT HTR2A PRL SLC6A4
21 substance abuse 29.5 BDNF COMT DRD2 DRD3 PRL SLC6A4
22 mood disorder 29.5 BDNF COMT DAOA DISC1 DISC2 DRD2
23 alcohol dependence 29.5 BDNF COMT DRD2 DRD3 HTR2A SLC6A4
24 bipolar disorder 29.5 BDNF COMT DAOA DISC1 DISC2 DRD2
25 major depressive disorder 29.1 BDNF COMT DISC1 DISC2 DRD2 DRD3
26 psychotic disorder 28.7 BDNF COMT DAOA DISC1 DRD2 DRD3
27 schizophrenia 4 11.0
28 schizophrenia 9 11.0
29 schizophrenia 15 11.0
30 chromosome 2p16.3 deletion syndrome 11.0
31 schizophrenia 18 11.0
32 schizophrenia 19 11.0
33 galactorrhea 10.2 DRD2 PRL
34 substance-induced psychosis 10.2 DRD2 HTR2A
35 prolactin producing pituitary tumor 10.2 DRD2 PRL
36 schizophrenia 5 10.2 COMT HTR2A
37 impulse control disorder 10.2 DRD2 DRD3
38 polysubstance abuse 10.2 COMT DRD2 DRD3
39 mammographic density 10.2 COMT PRL
40 atypical depressive disorder 10.2 HTR2A SLC6A4
41 alcohol-induced mental disorder 10.2 DRD2 SLC6A4
42 bruxism 10.1 DRD2 DRD3 HTR2A
43 psychosexual disorder 10.1 HTR2A SLC6A4
44 social phobia 10.1 DRD2 PRL SLC6A4
45 opiate dependence 10.1 DRD2 DRD3 SLC6A4
46 oppositional defiant disorder 10.1 COMT DRD2 SLC6A4
47 phobic disorder 10.1 COMT SLC6A4
48 alexithymia 10.1 COMT DRD2 SLC6A4
49 cocaine abuse 10.1 DRD2 PRL SLC6A4
50 antisocial personality disorder 10.1 COMT DRD2 SLC6A4

Graphical network of the top 20 diseases related to Schizoaffective Disorder:



Diseases related to Schizoaffective Disorder

Symptoms & Phenotypes for Schizoaffective Disorder

MGI Mouse Phenotypes related to Schizoaffective Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.93 BDNF COMT DISC1 DRD2 DRD3 DTNBP1
2 homeostasis/metabolism MP:0005376 9.73 BDNF COMT DISC1 DRD2 DRD3 DTNBP1
3 nervous system MP:0003631 9.44 BDNF COMT DISC1 DRD2 DRD3 DTNBP1

Drugs & Therapeutics for Schizoaffective Disorder

Drugs for Schizoaffective Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 398)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
2
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106266-06-2 5073
3
Haloperidol Approved Phase 4,Phase 3,Not Applicable 52-86-8 3559
4
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 132539-06-1 4585
5
Chlorpromazine Approved, Investigational, Vet_approved Phase 4 50-53-3 2726
6
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129722-12-9 60795
7
Ziprasidone Approved Phase 4,Phase 2,Phase 3,Not Applicable 146939-27-7 60854
8
Citalopram Approved Phase 4,Not Applicable 59729-33-8 2771
9
Armodafinil Approved, Investigational Phase 4,Phase 2,Phase 1 112111-43-0
10
Modafinil Approved, Investigational Phase 4,Phase 2,Phase 1 68693-11-8 4236
11
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
12
Donepezil Approved Phase 4 120014-06-4 3152
13
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
14
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
15
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
16
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
17
Clozapine Approved Phase 4,Phase 1,Not Applicable 5786-21-0 2818
18
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 22916-47-8 4189
19
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 1 10118-90-8 5281021
20
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
21
Ondansetron Approved Phase 4,Phase 2,Phase 1 99614-02-5 4595
22
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 1 99-66-1 3121
23
Pravastatin Approved Phase 4 81093-37-0 54687
24
Galantamine Approved Phase 4,Phase 3,Phase 2 357-70-0 9651
25
Nicotine Approved Phase 4,Phase 2,Phase 3,Not Applicable 54-11-5 942 89594
26
Lorazepam Approved Phase 4,Phase 3,Phase 2 846-49-1 3958
27
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
28
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
29
Amphetamine Approved, Illicit, Investigational Phase 4,Phase 2 300-62-9 5826 3007
30
Cocaine Approved, Illicit Phase 4,Phase 3 50-36-2 5760 446220
31
Perphenazine Approved Phase 4,Not Applicable 58-39-9 4748
32
Zinc Approved, Investigational Phase 4 7440-66-6
33
Metformin Approved Phase 4,Phase 3 657-24-9 14219 4091
34
Naltrexone Approved, Investigational, Vet_approved Phase 4,Not Applicable 16590-41-3 5360515
35
Ethanol Approved Phase 4,Phase 1,Phase 2,Not Applicable 64-17-5 702
36
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
37
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
38
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
39
Allopurinol Approved Phase 4 315-30-0 2094
40
Lithium carbonate Approved Phase 4,Phase 2,Phase 1 554-13-2
41
Acetylcholine Approved Phase 4,Phase 2 51-84-3 187
42
Sulpiride Approved, Investigational Phase 4,Not Applicable 15676-16-1 5355
43
Molindone Approved Phase 4 7416-34-4 23897
44
Cycloserine Approved Phase 4,Phase 2,Phase 3,Not Applicable 68-41-7 6234 401
45
Fluphenazine Approved Phase 4 69-23-8 3372
46 bromperidol Approved, Investigational Phase 4 10457-90-6 2448
47 Perazine Approved, Investigational Phase 4 84-97-9
48 Benperidol Approved, Investigational Phase 4 2062-84-2
49
Fluspirilene Approved, Investigational Phase 4 1841-19-6 3396
50
Pimozide Approved Phase 4 2062-78-4 16362

Interventional clinical trials:

(show top 50) (show all 681)
# Name Status NCT ID Phase Drugs
1 High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone Unknown status NCT00539071 Phase 4 long-acting injectable risperidone;long acting injectable risperidone;long acting injectable risperidone
2 A Pharmacokinetic Study of Paliperidone ER Unknown status NCT02433717 Phase 4 Paliperidone ER
3 Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm Unknown status NCT01016145 Phase 4 Antipsychotics;Antipsychotics
4 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4 Escitalopram
5 Antipsychotic Effects on Brain Function in Schizophrenia Unknown status NCT01913327 Phase 4 Aripiprazole;Risperidone;Modafinil
6 Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia Unknown status NCT00469664 Phase 4 Guanfacine/Tenex
7 Donepezil Double Blind Trial for ECT Memory Disfunction Unknown status NCT00465283 Phase 4 Donepezil
8 The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation Unknown status NCT02935998 Phase 4 Ziprasidone
9 Prednisolone Addition for Patients With Recent-onset Psychotic Disorder Unknown status NCT02949232 Phase 4 Prednisolone;Placebo Oral Tablet
10 Reduction of Cardiovascular Risk in Severe Mental Illness Unknown status NCT01182012 Phase 4
11 Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder Completed NCT00100776 Phase 4 Olanzapine
12 A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective Disorder Completed NCT00253110 Phase 4 risperidone;haloperidol
13 An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment Completed NCT00526877 Phase 4 Risperidone
14 Equivalence of Generic Clozapine to Orally Dissolving Clozapine in Schizophrenia or Schizoaffective Disorder Completed NCT00501618 Phase 4 Fazaclo
15 An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders Completed NCT01855074 Phase 4 Risperidone
16 A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs Completed NCT00649064 Phase 4 Ziprasidone
17 A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder Completed NCT00206102 Phase 4 quetiapine fumarate;risperidone
18 A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder Completed NCT00650429 Phase 4 Ziprasidone
19 Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder Completed NCT00090012 Phase 4 Olanzapine;Quetiapine
20 Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder Completed NCT00373672 Phase 4 armodafinil (Nuvigil);placebo
21 Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)? Completed NCT00306475 Phase 4 divalproex sodium ER;placebo
22 Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder Completed NCT00061802 Phase 4 risperidone, quetiapine
23 A Clinical Trial to Examine Effects of Atomoxetine in the Treatment of Negative Symptoms in Patients With Schizophrenia Completed NCT00222794 Phase 4 Atomoxetine (Strattera)
24 Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone Completed NCT00406315 Phase 4 ziprasidone
25 Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin Completed NCT00177580 Phase 4 Pravastatin
26 Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder Completed NCT00190749 Phase 4 olanzapine;risperidone
27 Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder. Completed NCT00325689 Phase 4 Quetiapine or Risperidone + Aripiprazole;Quetiapine or Risperidone + placebo
28 A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients Completed NCT00634348 Phase 4 Aripiprazole;Ziprasidone
29 An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder Completed NCT00992407 Phase 4 Risperidone long acting injectables;Risperidone tablets
30 A Study Comparing Three Strategies to Switch Patients With Schizophrenia or Schizoaffective Disorder to Risperidone After Unsuccessful Treatment With Olanzapine. Completed NCT00378183 Phase 4 risperidone
31 Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder Completed NCT00423878 Phase 4 Risperidone;Olanzapine;Quetiapine;Aripiprazole
32 The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder Completed NCT00044187 Phase 4 Sibutramine
33 Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease Completed NCT00535145 Phase 4 Treatment as usual (TAU), Paliperidone ER
34 Galantamine for Cognition in People With Schizophrenia Completed NCT00320736 Phase 4 galantamine
35 Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia Completed NCT02137993 Phase 4 A-prexa;Zyprexa
36 Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS) Completed NCT00304655 Phase 4 Aripiprazole
37 Effectiveness of Ziprasidone for Patients With Schizophrenia Completed NCT01198353 Phase 4 Ziprasidone
38 Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder Completed NCT00137020 Phase 4 ziprasidone
39 A Study of the Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) in Patients With Schizophrenia or Schizoaffective Disorder Completed NCT00236379 Phase 4 Olanzapine;Risperidone
40 Nicotine Replacement Therapy for Smoking Cessation in Schizophrenia Completed NCT00320723 Phase 4 bupropion, transdermal nicotine patch
41 Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults Completed NCT00845507 Phase 4 Exenatide;Placebo
42 Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety Completed NCT00177008 Phase 4 Aripiprazole
43 Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia Completed NCT00208143 Phase 4 Quetiapine;Risperidone
44 Lurasidone Effects on Tissue Glutamate in Schizophrenia Completed NCT02199743 Phase 4 Lurasidone;Haloperidol;Perphenazine
45 Effect of Single Dose Intranasal Insulin On Cognitive Function Completed NCT00646581 Phase 4 Placebo;Insulin (Humulin)
46 The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study) Completed NCT00816907 Phase 4 Metformin;Placebo
47 A Comparison of Long-acting Injectable Medications for Schizophrenia Completed NCT01136772 Phase 4 haloperidol decanoate;paliperidone palmitate
48 Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics Completed NCT00458211 Phase 4 ziprasidone
49 Pregnenolone Augmentation in the Treatment of Patients With Recent-Onset Schizophrenia Completed NCT00847600 Phase 4
50 Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height) Completed NCT00303602 Phase 4 Sublingual orally disintegrating olanzapine (SODO);Oral olanzapine

Search NIH Clinical Center for Schizoaffective Disorder

Genetic Tests for Schizoaffective Disorder

Anatomical Context for Schizoaffective Disorder

MalaCards organs/tissues related to Schizoaffective Disorder:

41
Testes, Brain, Cortex, Liver, Bone, Prefrontal Cortex, Pituitary

Publications for Schizoaffective Disorder

Articles related to Schizoaffective Disorder:

(show top 50) (show all 750)
# Title Authors Year
1
A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder. ( 29619682 )
2018
2
Psychotropic Medication Use Among Adults With Schizophrenia and Schizoaffective Disorder in the United States. ( 29606075 )
2018
3
The Glasgow antipsychotic side-effects scale for clozapine in inpatients and outpatients with schizophrenia or schizoaffective disorder. ( 29125018 )
2018
4
Pharmacological treatment for schizoaffective disorder : A comparison with schizophrenia and bipolar disorder. ( 29564469 )
2018
5
Psychological Distress Among Caregivers of Individuals With a Diagnosis of Schizophrenia or Schizoaffective Disorder. ( 28967321 )
2018
6
Case series of diagnostic shift from bipolar disorder to schizoaffective disorder. ( 29189086 )
2018
7
Organization's Effects With Schizoaffective Disorder. ( 29325177 )
2018
8
Response after Infection-Associated Rise in Clozapine Levels in Treatment-Resistant Schizoaffective Disorder. ( 29623228 )
2018
9
A case report of schizoaffective disorder with ritualistic behaviors and catatonic stupor: successful treatment by risperidone and modified electroconvulsive therapy. ( 29534691 )
2018
10
Test-retest reliability of the diagnosis of schizoaffective disorder in childhood and adolescence - A systematic review and meta-analysis. ( 29360577 )
2018
11
Could schizoaffective disorder, schizophrenia and bipolar I disorder be distinguishable using cognitive profiles? ( 29852325 )
2018
12
Learning to Live With Schizoaffective Disorder: A Transformative Journey Toward Recovery. ( 29346672 )
2018
13
Life events in schizoaffective disorder: A systematic review. ( 29172048 )
2018
14
Impairment in delay discounting in schizophrenia and schizoaffective disorder but not primary mood disorders. ( 29808011 )
2018
15
Functional outcome and service engagement in major depressive disorder with psychotic features: comparisons with schizophrenia, schizoaffective disorder and bipolar disorder in a 6-year follow-up of the Cavan-Monaghan First Episode Psychosis Study (CAMFEPS). ( 29575682 )
2018
16
An evaluation of the differences in DNA damage in lymphocytes and repair efficiencies in patients with schizophrenia and schizoaffective disorder. ( 29960812 )
2018
17
Psoas Abscess as a Differential Diagnosis of Neuroleptic Malignant Syndrome in a Schizoaffective Disorder Patient With Catatonic Symptoms. ( 30444963 )
2018
18
Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate. ( 29766576 )
2018
19
Sequential type schizoaffective disorder: A concept missed in the classificatory system. ( 29990632 )
2018
20
Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate. ( 29992643 )
2018
21
BDNF Val66Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizoaffective disorder patients: a meta-analysis. ( 30181602 )
2018
22
EEG coherence in a mental arithmetic task performance in first episode schizophrenia and schizoaffective disorder. ( 30240977 )
2018
23
Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial. ( 30251622 )
2018
24
Cognitive Remediation Interventions in Schizoaffective Disorder: A Systematic Review. ( 30337889 )
2018
25
Real-world effectiveness of long-acting antipsychotic treatments in a nationwide cohort of 3957 patients with schizophrenia, schizoaffective disorder and other diagnoses in Quebec. ( 30344996 )
2018
26
Visuospatial and Sensory Integration Tasks in Patients With Schizophrenia or Schizoaffective Disorder: Relationship to Body Mass Index and Smoking. ( 30386258 )
2018
27
Does Schizoaffective Disorder explain the mental illnesses of Robert Schumann and Vincent Van Gogh? ( 30439846 )
2018
28
Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with schizophrenia or schizoaffective disorder. ( 30460884 )
2018
29
Structured lifestyle education to support weight loss for people with schizophrenia, schizoaffective disorder and first episode psychosis: the STEPWISE RCT. ( 30499443 )
2018
30
Heads Up: The Presentation of Schizoaffective Disorder in an Elite College Soccer Player with Prior Concussion. ( 29117025 )
2017
31
Genome-wide significant locus for Research Diagnostic Criteria Schizoaffective Disorder Bipolar type. ( 28851079 )
2017
32
Associations of NEUROD2 polymorphisms and change of cognitive dysfunctions in schizophrenia and schizoaffective disorder after eight weeks of antipsychotic treatment. ( 28470106 )
2017
33
Characteristics and Service Use of Older Adults with Schizoaffective Disorder Versus Older Adults with Schizophrenia and Bipolar Disorder. ( 28478998 )
2017
34
Prevalence, characteristics and management of headache experienced by people with schizophrenia and schizoaffective disorder: a cross sectional cohort study. ( 28747114 )
2017
35
Editorial Comment: Schizoaffective Disorder in Later Life: "Beware the Jabberwock". ( 28554538 )
2017
36
Clozapine, Diabetes Mellitus, Cardiovascular Risk and Mortality: Results of a 21-year Naturalistic Study in Patients with Schizophrenia and Schizoaffective Disorder. ( 29164928 )
2017
37
Blood serum concentrations of kynurenic acid in patients diagnosed with recurrent depressive disorder, depression in bipolar disorder, and schizoaffective disorder treated with electroconvulsive therapy. ( 28866716 )
2017
38
Remission of Schizoaffective Disorder Using Homeopathic Medicine: 2 Case Reports. ( 28987077 )
2017
39
Risk of gastrointestinal Hypomotility in schizophrenia and schizoaffective disorder treated with antipsychotics: A retrospective cohort study. ( 29107449 )
2017
40
The Effects of Psychoeducation on Long-term Inpatients with Schizophrenia and Schizoaffective Disorder. ( 28381728 )
2017
41
Self versus informant reports on the specific levels of functioning scale: Relationships to depression and cognition in schizophrenia and schizoaffective disorder. ( 28740827 )
2017
42
A neuropsychiatric case report: KlA1ver-Bucy and Gastaut-Geschwind syndromes in one patient with schizoaffective disorder presenting with brain 99-mTc HMPAO single-photon emission computed tomography showing bilateral discrete decrease of temporal lobes perfusion. ( 29061200 )
2017
43
Schizophrenia and induced abortions: A national register-based follow-up study among Finnish women born between 1965-1980 with schizophrenia or schizoaffective disorder. ( 28615119 )
2017
44
Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder. ( 28923068 )
2017
45
Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial. ( 28541645 )
2017
46
Schizoaffective disorder, catatonia and white matter changes - Revisiting the microglial hypothesis. ( 28349728 )
2017
47
A rare presentation of auto-emasculation in a patient with schizoaffective disorder: Management with clozapine. ( 28777030 )
2017
48
Impact of irritability: a 2-year observational study of outpatients with bipolar I or schizoaffective disorder. ( 28470892 )
2017
49
Measuring the Work Impact of Caregiving for Individuals With Schizophrenia and/or Schizoaffective Disorder With the Caregiver Work Limitations Questionnaire (WLQ). ( 28777200 )
2017
50
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder. ( 28839342 )
2017

Variations for Schizoaffective Disorder

Expression for Schizoaffective Disorder

Search GEO for disease gene expression data for Schizoaffective Disorder.

Pathways for Schizoaffective Disorder

Pathways related to Schizoaffective Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.99 COMT DTNBP1 NOTCH4 SLC1A1
2
Show member pathways
11.19 DRD2 DRD3 HTR2A
3 10.86 GABRB1 HTR2A SLC6A4
4 10.6 DRD2 DRD3

GO Terms for Schizoaffective Disorder

Cellular components related to Schizoaffective Disorder according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 glutamatergic synapse GO:0098978 9.76 DRD2 DRD3 DTNBP1 HTR2A
2 dendrite GO:0030425 9.72 BDNF COMT DRD2 GABRB1 HTR2A
3 postsynaptic membrane GO:0045211 9.71 COMT DISC1 DTNBP1 GABRB1
4 dendritic spine GO:0043197 9.67 COMT DRD2 DTNBP1
5 GABA-ergic synapse GO:0098982 9.54 DRD2 DRD3 GABRB1
6 dopaminergic synapse GO:0098691 9.43 DRD2 DRD3
7 integral component of presynaptic membrane GO:0099056 9.43 DRD2 HTR2A SLC6A4
8 axon GO:0030424 9.35 BDNF COMT DRD2 DTNBP1 HTR2A
9 integral component of postsynaptic membrane GO:0099055 9.33 DRD2 HTR2A SLC6A4
10 integral component of plasma membrane GO:0005887 9.23 DRD2 DRD3 GABRB1 HTR2A NOTCH4 PCDH11X
11 plasma membrane GO:0005886 10.22 COMT DISC1 DRD2 DRD3 DTNBP1 GABRB1

Biological processes related to Schizoaffective Disorder according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 response to ethanol GO:0045471 9.76 DRD2 DRD3 PRL
2 response to toxic substance GO:0009636 9.73 DRD2 GABRB1 SLC6A4
3 memory GO:0007613 9.71 BDNF HTR2A SLC6A4
4 regulation of synaptic vesicle exocytosis GO:2000300 9.65 DRD2 DTNBP1 HTR2A
5 arachidonic acid secretion GO:0050482 9.63 DRD2 DRD3
6 positive regulation of neuroblast proliferation GO:0002052 9.62 DISC1 DRD2
7 temperature homeostasis GO:0001659 9.62 DRD2 HTR2A
8 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.61 DRD2 DRD3
9 dopamine receptor signaling pathway GO:0007212 9.61 DRD2 DRD3
10 negative regulation of protein secretion GO:0050709 9.6 DRD2 DRD3
11 synaptic transmission, dopaminergic GO:0001963 9.59 DRD2 DRD3
12 prepulse inhibition GO:0060134 9.58 DRD2 DRD3
13 positive regulation of renal sodium excretion GO:0035815 9.57 DRD2 DRD3
14 G protein-coupled receptor internalization GO:0002031 9.55 DRD2 DRD3
15 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.52 DRD2 DRD3
16 ovulation cycle GO:0042698 9.51 GABRB1 PRL
17 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.49 DRD2 HTR2A
18 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.46 DRD2 DRD3
19 negative regulation of dopamine receptor signaling pathway GO:0060160 9.43 DRD2 DRD3
20 regulation of dopamine secretion GO:0014059 9.43 DRD3 DTNBP1 HTR2A
21 acid secretion GO:0046717 9.4 DRD2 DRD3
22 regulation of locomotion involved in locomotory behavior GO:0090325 9.37 DRD2 DRD3
23 behavioral response to cocaine GO:0048148 9.33 DRD2 DRD3 HTR2A
24 response to histamine GO:0034776 9.32 DRD2 DRD3
25 dopamine metabolic process GO:0042417 9.13 COMT DRD2 DRD3
26 response to drug GO:0042493 9.1 COMT DRD2 DRD3 HTR2A PRL SLC6A4

Molecular functions related to Schizoaffective Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 adrenergic receptor activity GO:0004935 9.37 DRD2 DRD3
2 drug binding GO:0008144 9.33 DRD2 DRD3 HTR2A
3 dopamine binding GO:0035240 9.32 DRD2 DRD3
4 serotonin binding GO:0051378 9.26 HTR2A SLC6A4
5 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 8.96 DRD2 DRD3
6 dopamine neurotransmitter receptor activity GO:0004952 8.62 DRD2 DRD3

Sources for Schizoaffective Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....